Table 2 Comparison of patient characteristics across HARMONY NPM1-mut risk categories.

From: Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study

 

NPM1 Favorable (n = 519)

NPM1 Intermediate (n = 248)

NPM1 Adverse (n = 234)

p-value

Female sex

275 (53%)

134 (54%)

134 (57.3%)

0.5500

Median age in years (range)

52.2 [18–81]

53.1 [18.8–80]

52.3 [24–77]

0.5290

 Age ≥60 years

136 (26.2%)

72 (29%)

61 (26.1%)

0.6758

AML type

    

 De novo AML

497 (95.8%)

238 (96%)

228 (97.4%)

0.5249

 Secondary AML

22 (4.2%)

10 (4%)

6 (2.6%)

  Prior HM

10 (1.9%)

4 (1.6%)

1 (0.4%)

0.2885

  Therapy-related AML

12 (2.3%)

6 (2.4%)

5 (2.6%)

0.9783

Hemoglobin (g/dL)

9.15

[Q1 = 7.8, Q3 = 10.4]

8.89

[Q1 = 7.5, Q3 = 10]

8.65

[Q1 = 7.5, Q3 = 10.4]

0.2938

WBC (x10^9/L)

14.2

[Q1 = 4.7, Q3 = 42.5]

26.8

[Q1 = 8.6, Q3 = 71.2]

50.6

[Q1 = 22, Q3 = 93.9]

< 0.0001

 WBC > 100 ×10^9/L

37 (7.1%)

44 (17.7%)

55 (23.5%)

< 0.0001

Platelets (x10^9/L)

68

[Q1 = 38, Q3 = 118]

67

[Q1 = 39, Q3 = 120.5]

63

[Q1 = 38, Q3 = 104]

0.5066

Bone marrow % of blasts

66

[Q1 = 36, Q3 = 86]

79.5

[Q1 = 52, Q3 = 90]

80

[Q1 = 63, Q3 = 90]

< 0.0001

ELN 2022

    

 Favorable

459 (88.4%)

141 (56.9%)

0 (0%)

< 0.0001

 Intermediate

52 (10%)

106 (42.7%)

234 (100%)

 Adverse

8 (1.5%)

1 (0.4%)

0 (0%)

FLT3-ITD present

52 (10%)

107 (43.1%)

234 (100%)

< 0.0001

Treatment response

    

 CRc

471 (90.7%)

207 (83.5%)

196 (83.7%)

< 0.0001

 Refractory

30 (5.8%)

30 (12.1%)

29 (12.5%)

 Not evaluable

18 (3.5%)

11 (4.4%)

9 (3.8%)

Early death

    

 30-day mortality

18 (3.5%)

11 (4.4%)

9 (3.8%)

0.7317

 60-day mortality

28 (5.4%)

21 (8.5%)

13 (5.6%)

0.2298

Allogeneic HSCT

131 (25.2%)

94 (37.9%)

116 (49.6%)

< 0.0001

 In CR1

93 (17.9%)

56 (22.6%)

93 (39.8%)

0.0011

 In other situations

38 (7.3%)

38 (15.3%)

23 (9.8%)

Median survival in years (95% CI)

14.37 (9.51–NA)

2.56 (1.98–4.38)

1.13 (0.966–1.5)

< 0.001

  1. AML acute myeloid leukemia, HM hematological malignancy, WBC white blood count, ELN European LeukemiaNet, ITD internal tandem duplication, CRc composite complete remission, HSCT hematopoietic stem cell transplantation, CR1 first complete remission, CI confidence interval.
Back to article page